Robo Global Robotics and Automation Index ETF (ROBO)
- Previous Close
53.75 - Open
53.84 - Bid 52.49 x 1100
- Ask 58.67 x 900
- Day's Range
53.38 - 54.10 - 52 Week Range
45.42 - 60.29 - Volume
41,322 - Avg. Volume
72,312 - Net Assets 1.35B
- NAV 53.90
- PE Ratio (TTM) 27.88
- Yield 0.05%
- YTD Daily Total Return -6.42%
- Beta (5Y Monthly) 1.40
- Expense Ratio (net) 0.95%
The fund will normally invest at least 80% of its total assets in securities of the index or in depositary receipts representing securities of the index. The index is designed to measure the performance of robotics-related and/or automation-related companies. The fund may invest up to 20% of its assets in investments that are not included in the index, but which the Adviser and Sub-Adviser believe will help it track the index. It is non-diversified.
Robo Global
Fund Family
Global Small/Mid Stock
Fund Category
1.35B
Net Assets
2013-10-22
Inception Date
Performance Overview: ROBO
Trailing returns as of 4/18/2024. Category is Global Small/Mid Stock.
People Also Watch
Holdings: ROBO
Top 10 Holdings (17.16% of Total Assets)
Sector Weightings
Recent News: ROBO
Research Reports: ROBO
Analyst Report: Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns one resource, Thacker Pass, that is located in northwest Nevada. Thacker Pass recently began construction and is expected to begin production in the mid to late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
RatingBullishPrice TargetAnalyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingBullishPrice TargetFTNT: What does Argus have to say about FTNT?
FORTINET INC has an Investment Rating of HOLD; a target price of $71.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingNeutralPrice TargetFTNT: Lowering target price to $71.00
FORTINET INC has an Investment Rating of HOLD; a target price of $71.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice Target